Denali Therapeutics Inc
NASDAQ:DNLI
Denali Therapeutics Inc
NASDAQ:DNLI
Price:
20.77 USD
-2.53%
Market Closed
Updated:
Jun 9, 2024
Denali Therapeutics Inc
Long-Term Investments
|
Denali Therapeutics Inc
Long-Term Investments Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Long-Term Investments Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Long-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Denali Therapeutics Inc
NASDAQ:DNLI
|
Long-Term Investments
$490.7m
|
CAGR 3-Years
133%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Long-Term Investments
$305m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Long-Term Investments
$359m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Long-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Long-Term Investments
$4.5B
|
CAGR 3-Years
496%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Long-Term Investments
$7B
|
CAGR 3-Years
25%
|
CAGR 5-Years
24%
|
CAGR 10-Years
29%
|
See Also
What is Denali Therapeutics Inc's Long-Term Investments?
Long-Term Investments
490.7m
USD
490.7m
USD
Based on the financial report for Mar 31, 2024, Denali Therapeutics Inc's Long-Term Investments amounts to 490.7m USD.
What is Denali Therapeutics Inc's Long-Term Investments growth rate?
Long-Term Investments CAGR 5Y
38%
38%
The average annual Long-Term Investments growth rates for Denali Therapeutics Inc have been 133% over the past three years , 38% over the past five years .
You don't have any saved screeners yet
